DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
Same disease, same payment across tiers. Of 31 DRG categories, 27 are internal medicine, where drug cost rather than theatre time drives the case.
Listing is granted by indication, not by licence. Columvi is funded for one situation and refused for the rest of its authorisation.
First and only is not the same as available. One authorisation covers 30 jurisdictions, each of which now prices the drug separately.
QuickAccess read/Endocrine & Metabolic/Peptide NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option Athithi Verma· 25 August 2026· 2 min read· Synopulse NICE published final draft guidance recommending insulin efsitora alfa (Onswik), from Eli Lilly, for adults with type 2 diabetes. Given once weekly by pre-filled … Read more
One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
Two carriers built new pharma lanes in five weeks. Both end at Heathrow, an airport that lost a day to one transformer fire in March 2025.
The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.